Short answer
Charles River Laboratories (CRL) filed its fiscal 2025 10-K annual report with the SEC on Feb 18, 2026. It reported revenue of $4.0B (−0.9% year over year) and net income of −$144M.
- Top risk flagged: Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
FY2025 key financial metrics · XBRL
- Revenue
- $4.0B
- −0.9% YoY
- Net income
- −$144M
- −750.1% YoY
- Operating margin
- 0.6%
- −5.0 pp YoY
- EPS (diluted)
- −$2.91
- −1555.0% YoY
- ROE
- -4.6%
- −5.2 pp YoY
- Operating cash flow
- $738M
- +0.4% YoY
Source: XBRL data from the Charles River Laboratories (CRL) FY2025 10-K on SEC EDGAR. USD.
Charles River Laboratories FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Preclinical and clinical laboratory services for drug discovery and development
- No new products, services, or business segments introduced or emphasized in this fiscal year
- Maintained existing strategic practices, including strict compliance on timing of equity awards and insider trading policies
- Fiscal 2025 equity awards policy with no stock options granted near earnings releases to avoid insider trading risks
- No errors or clawbacks of executive compensation reported during or after fiscal 2025
Management Discussion & Analysis
- Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
- Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
- Best segment: Manufacturing Microbial Solutions with robust growth, share gains, and higher sales; Worst segment: DSA with declined revenue and backlog falling to $1.9B from $2.0B
- Capital allocation: Acquired KF for $510M, Noveprim controlling interest for $392.4M, SAMDI for $62.8M, PathoQuest option for ~$60M; acquisitions funded by cash and Credit Facility
- Forward outlook: $300M cost savings by 2026; focus on strategic acquisitions, partnerships, and divestments of 7% 2025 revenue; cautious early-stage R&D spending remains a risk
Risk Factors
- Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
- Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
- Cybersecurity assessments include third-party audits, vulnerability tests, and industry standard compliance frameworks
- Incident Response Plan mandates escalation to Audit Committee for significant cybersecurity events
- No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.